PRIMARY STUDY ENDPOINTS FROM PHASE III CLINICAL TRIAL OF CM310 FOR THE TREATMENT OF MODERATE TO SEVERE ATOPIC DERMATITIS IN ADULTS

Keymed and InnoCare Jointly Announce First Subject Dosed in Clinical Trial of CCR8 Monoclonal Antibody CM369

Keymed Biosciences announces dosing of first patient in Phase I trial of bispecific antibody CM350

Keymed Biosciences released positive result from Phase II clinical trial of CM310 at CRSwNP

Keymed and InnoCare jointly announce dosing of first patient in clinical trial of CD20xCD3 bispecific antibody CM355